1. Home
  2. MYO vs XLO Comparison

MYO vs XLO Comparison

Compare MYO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$1.28

Market Cap

68.9M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$9.00

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MYO
XLO
Founded
2004
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.9M
56.9M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
MYO
XLO
Price
$1.28
$9.00
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$7.67
$28.00
AVG Volume (30 Days)
631.6K
9.5K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000,000.00
$43,766,000.00
Revenue This Year
$9.10
N/A
Revenue Next Year
$13.59
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
40814.79
589.88
52 Week Low
$0.61
$0.46
52 Week High
$1.89
$9.90

Technical Indicators

Market Signals
Indicator
MYO
XLO
Relative Strength Index (RSI) 45.27 48.51
Support Level $0.92 $8.52
Resistance Level $1.89 $9.15
Average True Range (ATR) 0.14 0.29
MACD -0.05 -0.02
Stochastic Oscillator 5.05 57.33

Price Performance

Historical Comparison
MYO
XLO

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: